2096.HK Stock Analysis
20
Uncovered
Simcere Pharmaceutical Group Ltd is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Simcere Pharmaceutical Group Ltd. engages in the research, development, manufacturing, and sale of pharmaceutical products. The company is headquartered in Nanjing, Jiangsu and currently employs 6,542 full-time employees. The company went IPO on 2020-10-27. The firm's main products are generic drugs, including Bicun used for central nervous system diseases, Jepaso and Jiebaili used for oncology, as well as Yingtaiqing used for autoimmune diseases. The firm also produces innovative drugs, such as Endostar used for oncology. The firm is also involved in providing promotion services for third-party drugs sold by medical institutions.